Tamtuvetmab
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA) . Tamtuvetmab has been approved by veterinary[1][2].
Product Specifications
CAS Number
1608122-71-9
Product Name Alternative
AT-005
UNSPSC
12352203
Target
NF-κB
Type
Inhibitory Antibodies
Related Pathways
NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tamtuvetmab.html
Purity
97
Solubility
10 mM in DMSO
Smiles
[Tamtuvetmab]
Molecular Weight
(146.346 kDa)
References & Citations
[1]Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9 (1) :e49. |[2]Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY418993 100 µg
Psoriasin (S100A7) (NM_002963) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC941574-500 1x 500 µL
HIF1 alpha (Hypoxia-Inducible Factor 1-alpha) (ESEE122), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details